|
Adrenal steroids do the heavy lifting in the body's natural defense and metabolic systems, and Hollis-Eden Pharmaceuticals hopes to harness their power. The company focuses on developing adrenal steroid hormones and hormone analogs, which may reduce inflammation, regulate immunity, and stimulate cell growth. Natural levels of adrenal steroid hormones can decline as a result of aging or stress, leaving the body less able to fend off illnesses. Hollis-Eden Pharmaceuticals' leading drug candidate TRIOLEX is being tested as a possible treatment for type 2 diabetes, rheumatoid arthritis, and ulcerative colitis. Its APOPTONE candidate is being investigated as a therapy for prostate and breast cancer.
|
| | | Contact Information | |
Address: |
4435 Eastgate Mall, Ste. 400
San Diego, CA 92121
| | Phone: | 858-587-9333 | | Fax: | 858-558-6470 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.00 M | | Employees (2008): | 42 | | Employee Growth (1 yr): | (-25.00%) |
|
|
Key People
| | • |
Chairman:
Salvatore J. Zizza
| | • |
President, CEO, and Director:
James M. Frincke
| | • |
VP Operations, Interim CFO, Controller, Secretary, and Chief:
Robert W. Weber
|
|
|
